Lassa fever resources

PPE washing and drying station Lassa ward Owo

ISARIC is committed to strengthening the evidence base for Lassa fever therapeutics and improving case management. We have initiated a number of activities to address these knowledge gaps, which are conducted alongside a wide-range of partners and collaborators.

Introduction to Lassa Fever

Tile subhead - What is Lassa fever? Context and treatments.

Lassa fever: addressing knowledge gaps

Tile subhead - How can case management and treatment outcomes be improved?

Ribavirin and supportive care

Tile subhead - Analyses of current treatments for Lassa.

West Africa Lassa fever Consortium (WALC)

Tile subhead - Explore WALC's framework for Lassa fever treatment.

Publication library

Visit this section to find ISARIC’s articles, studies and more.

Latest news

Children hospitalised with Omicron did not have a higher risk of experiencing long-term health issues compared to other infections, finds latest study

Children hospitalised with Omicron did not have a higher risk of experiencing long-term health issues compared to other infections, finds latest study

8 February 2024: A new study finds that children hospitalised with initial COVID-19 variant showed more signs of dermatological, fatigue, gastrointestinal, sensory, and sleep issues, as well as behavioural and emotional problems.

Public health vision led by ISARIC partners aims to tackle Nipah virus

Public health vision led by ISARIC partners aims to tackle Nipah virus

15 January 2024: In a new paper published in The Lancet Infectious Diseases, researchers based in Bangladesh, Oxford and Geneva call for a comprehensive public health framework to counter Nipah virus and other neglected infectious diseases with pandemic potential.

Draft Framework for Clinical Trials Now Open for Feedback

Draft Framework for Clinical Trials Now Open for Feedback

18 December 2023: The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) is working with partners to create a framework on endpoint selection for clinical trials for outbreak-prone infectious diseases. This call for a public consultation invites feedback on what the framework does well, what could be improved and the limits of its potential application.